Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05454280 · ClinicalTrials.gov registry record · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
A Phase 3 study of Cancer and Surgery, sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 880
- Enrollment target
- 1
- Study location
NCT05454280: Recruiting Phase 3 study of Cancer and Surgery, sponsored by Fox Chase Cancer Center.
NCT05454280 is a Phase 3 study of Cancer and Surgery that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 880 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05454280, a Phase 3 study of Cancer and Surgery, is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 880 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).
Primary Outcome
The primary objective of this trial is to determine if intensified post-discharge surveillance leads to a 7% absolute risk reduction/35% relative risk reduction in the composite endpoint of 30-day rate of readmission/visit to emergency department/death compared to standard post discharge management in patients undergoing elective, high risk cancer operations.
Interventions
- PROCEDURE Intensified post-discharge surveillance
- PROCEDURE Standard post-discharge surveillance
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2022-10-14 |
| Est. Completion | 2028-11-01 |
| Phase | Phase 3 |
What NCT05454280 shows while recruiting
NCT05454280 is an interventional study that assigns participants to a tested intervention. The registered 880 participants enrollment target is mid-sized for trials with a published cap, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Intensified post-discharge surveillance is the first listed.
NCT05454280 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05454280 about?
NCT05454280 is a clinical study titled "Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)". This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).
What is the current status of trial NCT05454280?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 880 participants. The study started on 2022-10-14. Estimated completion is 2028-11-01.
What conditions does trial NCT05454280 study?
This clinical trial studies the following conditions: Cancer, Surgery.
What interventions are being tested in trial NCT05454280?
The interventions under investigation include: Intensified post-discharge surveillance (PROCEDURE), Standard post-discharge surveillance (PROCEDURE).
Who is sponsoring clinical trial NCT05454280?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05454280 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05454280's enrollment target sits among peer trials
880 89th of 615 higher than 527 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
RECRUITING · Phase 3
-
DOAC - Dosing Options in AntiCoagulation Prophylaxis
RECRUITING · Phase 3
-
Abatacept in Immune Checkpoint Inhibitor Myocarditis
RECRUITING · Phase 3
-
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITING · Phase 3
-
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
RECRUITING · Phase 3
-
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
- NCT06580314 · 880 participants · Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- NCT06624202 · 880 participants · NA
COmmunities Aligned to Reduce Concussion and Head Impact Exposure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI